Gene · 6844
VAMP2: vesicle associated membrane protein 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. VAMP2: vesicle associated membrane protein 2. Genes, record 6844. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6844
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P63027 | Vesicle-associated membrane protein 2 | 116 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents104
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69647 | P63027 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4947 | P63027 | Espacenet |
| JP 2025533447 A | 2025-10-07 | 32 | P63027 | Espacenet |
| WO 2025196445 A1 | 2025-09-25 | 25 | P63027 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5214 | P63027 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5214 | P63027 | Espacenet |
| US 12344634 B2 | 2025-07-01 | 9 | P63027 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4947 | P63027 | Espacenet |
| KR 1020250069908 A | 2025-05-20 | 32 | P63027 | Espacenet |
| US 12209269 B2 | 2025-01-28 | 17 | P63027 | Espacenet |
1 to 10 of 104
See all 104 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| RIMABOTULINUMTOXINB | CHEMBL1201569 | Vesicle-associated membrane protein 2 inhibitor | INHIBITOR |
Source ChEMBL
Trials15
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05097079 | RIMABOTULINUMTOXINB | PHASE3 | ClinicalTrials.gov | |
| NCT04815967 | RIMABOTULINUMTOXINB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04099667 | RIMABOTULINUMTOXINB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT03103074 | RIMABOTULINUMTOXINB | ClinicalTrials.gov | ||
| NCT02610868 | RIMABOTULINUMTOXINB | PHASE3 | 2019-11-04 | ClinicalTrials.gov |
| NCT02212119 | RIMABOTULINUMTOXINB | PHASE2 | ClinicalTrials.gov | |
| NCT02002923 | RIMABOTULINUMTOXINB | PHASE2 | ClinicalTrials.gov | |
| NCT01994109 | RIMABOTULINUMTOXINB | PHASE3 | 2019-08-15 | ClinicalTrials.gov |
| NCT01930604 | RIMABOTULINUMTOXINB | PHASE2 | ClinicalTrials.gov | |
| NCT00702754 | RIMABOTULINUMTOXINB | PHASE4 | 2009-09-23 | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsNIH grants1,964
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | VAMP2 papers | Newest fiscal year |
|---|---|---|---|
| R01MH061876 | Synaptotagmin C2B Domain as a Ca2+ Sensing Module | 14 | 2025 |
| R01NS080833 | Biology and Engineering of Botulinum Neurotoxins. | 10 | 2025 |
| P30DK034854 | Integrated Epithelial and Muscosal Biology | 8 | 2025 |
| P50HD103537 | Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt | 6 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 5 | 2025 |
| R01AI093504 | Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | 5 | 2025 |
| R01MH070727 | Antidepressants and Intracellular Signaling Linked to BDNF | 5 | 2025 |
| R35GM131714 | Single-molecule studies of SNARE assembly and lipid transfer | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
1 to 10 of 1,964Source NIH's project files
See all 1,964 nih grantsPapers2,700
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dual effect of α-synuclein disease variants on condensate formation. | Nat Commun | 2026 | 42823411 | PubTator, text mining | PubMed |
| Development of novel human monoclonal antibodies for botulinum neurotoxin type F subtype 1. | Jpn J Infect Dis | 2026 | 42816359 | PubTator, text mining | PubMed |
| Correction: Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer's disease and Parkinson's disease. | Alzheimers Res Ther | 2026 | 42800866 | PubTator, text mining | PubMed |
| Synaptobrevin-2 Containing Extracellular Vesicles Are Rapidly Incorporated Into Mammalian Neurons via a Dynamin-Dependent Pathway. | J Neurochem | 2026 | 42725393 | PubTator, text mining | PubMed |
| Pathogenic KIF1A variants differentially disrupt axonal trafficking and impede synaptic development. | J Cell Biol | 2026 | 42704317 | PubTator, text mining | PubMed |
| Oligomeric Alpha-Synuclein from neural-derived extracellular vesicles as possible biomarkers of non-motor symptoms in Parkinson's disease. | NPJ Parkinsons Dis | 2026 | 42649220 | PubTator, text mining | PubMed |
| Light-activated tetanus neurotoxin for conditional proteolysis and inducible synaptic inhibition in vivo. | Nat Methods | 2026 | 42533122 | PubTator, text mining | PubMed |
| Munc18 binds to and organizes membrane-bound acceptor Q-SNARE complexes in a fashion that depends on the membrane's lipid composition. | bioRxiv | 2026 | 42523309 | PubTator, text mining | PubMed |
| Value of synaptic proteins as biomarkers in amyotrophic lateral sclerosis. | Brain Commun | 2026 | 42404435 | PubTator, text mining | PubMed |
| SNAREopathy in Neurologic Disorders: From Synaptic Mechanisms to Genetic and Epigenetic Regulation. | Neuroscientist | 2026 | 42403099 | PubTator, text mining | PubMed |
1 to 10 of 2,700
See all 2,700 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6844
GET https://conductscience.org/api/genes/v1/6844/patents?page=2